Skip to main content

Table 1 Incidence of total adverse reactions among vaccination group versus control group

From: Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials

  No. of studies Reactions/total RR (95% CI) I2
Vaccination Control
Overall
 Total adverse reactions 10 33 673/54 752 16 446/52 400 1.75 (1.59–1.92)* 0.93
 Systemic adverse reactions (any) 7 25 286/39 698 14 972/38 088 1.41 (1.11–1.78)* 0.99
 Local adverse reactions (any) 7 32 077/39 698 6687/38 088 4.49 (3.79–5.30)* 0.94
Total adverse reactions to different vaccine types
 Inactivated vaccine 5 523/2244 107/630 1.34 (1.11–1.61)* 0.00
 Vectored vaccine 2 670/886 177/382 1.65 (1.31–2.07)* 0.75
 mRNA vaccine 3 32 480/51 622 16 162/51 388 2.01 (1.78–2.26)* 0.98
Systemic adverse reactions (any) to different vaccine types
 Inactivated vaccine 4 193/1764 52/468 0.92 (0.69–1.23) 0.00
 mRNA vaccine 2 25 020/37 696 14 911/37 560 1.65 (1.21–2.24)* 1.00
Local adverse reactions (any) to different vaccine types
 Inactivated vaccine 4 172/1164 29/320 1.94 (1.10–3.41)* 0.54
 mRNA vaccine 2 31 735/37 696 6653/37 560 5.37 (4.54–6.36)* 0.98
Fever
 Inactivated vaccine 5 64/2244 16/630 0.99 (0.56–1.73) 0.00
 Vectored vaccine 3 410/1121 80/968 3.05 (1.56–5.99)* 0.84
 mRNA vaccine 5 3175/38 365 128/37 591 7.90 (2.72–22.94)* 0.95
Headache
 Inactivated vaccine 4 22/1644 6/480 0.72 (0.29–1.77) 0.00
 Vectored vaccine 3 555/1121 311/968 1.68 (1.51–1.86)* 0.00
 mRNA vaccine 5 17 152/38 365 9300/37 591 2.06 (1.49–2.83)* 0.99
Fatigue
 Inactivated vaccine 5 88/2244 6/630 0.85 (0.55–1.30) 0.00
 Vectored vaccine 3 639/1121 334/968 1.88 (1.31–2.69)* 0.81
 mRNA vaccine 5 19 471/38 365 9506/37 591 1.98 (1.46–2.67)* 0.99
Pain
 Inactivated vaccine 5 329/2244 39/630 2.24 (1.37–3.65)* 0.50
 Vectored vaccine 2 573/925 209/660 3.29 (0.92–11.77) 0.95
 mRNA vaccine 4 31 924/38 065 5946/37 519 5.63 (4.89–6.48)* 0.93
Redness
 Inactivated vaccine 5 15/2244 2/630 0.90 (0.32–2.59) 0.00
 Vectored vaccine 2 22/925 13/660 1.34 (0.67–2.65) 0.00
 mRNA vaccine 3 2127/37 650 194/37 457 7.59 (3.74–15.39)* 0.93
Swelling
 Inactivated vaccine 4 19/1644 3/480 1.08 (0.39–3.03) 0.00
 Vectored vaccine 2 37/925 18/660 2.23 (0.33–14.96) 0.53
 mRNA vaccine 4 3843/38 065 149/37 519 12.69 (6.50–24.79)* 0.89
Total adverse reactions of different sample sizes
 Sample size ≥ 500 5 32 976/52 928 16 246/51 758 1.95 (1.75–2.17)* 0.97
 Sample size < 500 6 697/1824 200/652 1.43 (1.25–1.64)* 0.12
Total adverse reactions of different trial phases
 Phase I trial 4 137/468 26/155 1.62 (1.12–2.36)* 0.00
 Phase II trial 5 650/1966 120/564 1.49 (1.14–1.94)* 0.54
 Phase III trial 2 32 423/51 466 16 154/51 352 2.03 (1.79–2.29)* 0.99
  1. RR risk ratios, CI confidence interval, No. Number
  2. *P < 0.05